Return to homepagePandemic Pact

Task D07: GLP 28-day repeat toxicology and cardiovascular telemetry assessment of Lassa antiviral in cynomolgus macaques

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 272201800001I-0-759302100007-1

Grant search

Key facts

  • Disease

    Lassa Haemorrhagic Fever

  • Start & end year

    2021
    2022

  • Known Financial Commitments (USD)

    $1,766,053

  • Funder

    National Institutes of Health (NIH)

  • Principal Investigator

    JON MIRSALIS

  • Research Location

    United States of America

  • Lead Research Institution

    SRI INTERNATIONAL

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    Innovation

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

The Non-clinical Services for Development of Interventional Agents for Infectious Diseases program provides services to facilitate preclinical product development of promising therapeutics for infectious disease-causing pathogens and/or toxins. Services include: preclinical product development planning and evaluation; lead identification and development; chemistry and GMP manufacturing; in vitro and in vivo preclinical microbiological, safety, toxicology and pharmacokinetics.